thalidomide has been researched along with Central Nervous System Disease in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duzova, A | 1 |
| Bakkaloglu, A | 1 |
| Ahn, SW | 1 |
| Kim, KT | 1 |
| Youn, YC | 1 |
| Kwon, OS | 1 |
| Kim, YB | 1 |
| MICHAELIS, R | 1 |
| TARNOW, G | 1 |
| Broekaert, SM | 1 |
| Metzler, G | 1 |
| Burgdorf, W | 1 |
| Röcken, M | 1 |
| Schaller, M | 1 |
| Archer, J | 1 |
| Naafs, B | 1 |
| Faber, WR | 1 |
| Amelung, W | 1 |
| Püntmann, E | 1 |
| Horstmann, W | 1 |
1 review available for thalidomide and Central Nervous System Disease
| Article | Year |
|---|---|
Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment.
Topics: Anticonvulsants; Central Nervous System Diseases; Child; Cyclophosphamide; Drug Therapy, Combination | 2008 |
7 other studies available for thalidomide and Central Nervous System Disease
| Article | Year |
|---|---|
Isolated spinal cord neurosarcoidosis diagnosed by cord biopsy and thalidomide trial.
Topics: Adrenal Cortex Hormones; Biopsy; Central Nervous System Diseases; Female; Humans; Immunosuppressive | 2011 |
[NEUROLOGICAL DISEASES AS SEQUELS TO CONTERGAN USE IN DISORDERS OF INTESTINAL RESORPTION].
Topics: Central Nervous System Diseases; Gastric Acidity Determination; Gastritis; Intestinal Diseases; Neur | 1963 |
Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide.
Topics: Anti-Inflammatory Agents; Central Nervous System Diseases; Female; Histiocytosis, Langerhans-Cell; H | 2007 |
Thalidomide and neurological damage revisited.
Topics: Abnormalities, Drug-Induced; Central Nervous System Diseases; Female; Fetus; Humans; Infant, Newborn | 1978 |
Thalidomide therapy. An open trial.
Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu | 1985 |
[Clinical aspects and therapy of the so-called Contergan-polyneuropathy].
Topics: Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Nerve Degeneration; | 1966 |
[Reference to central nervous system damage within the context of thalidomide embryopathy. Pathological-anatomic, electroencephalographic and neurologic findings].
Topics: Abnormalities, Drug-Induced; Central Nervous System Diseases; Child, Preschool; Ear Deformities, Acq | 1966 |